Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
Facing declining core automotive revenue, Tesla announces a radical strategic shift, halting production of flagship luxury models to fund a massive push into robotics and autonomous vehicles. Investors are left weighing ambitious promises against a backdrop of financial strain.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Igor Runets, founder and CEO of Russia's largest Bitcoin mining operator BitRiver, has been detained and placed under house arrest on charges of large-scale tax evasion. The case unfolds against a backdrop of Western sanctions and operational challenges for the once-dominant firm.
D-Wave Quantum Inc. announces the relocation of its headquarters and core R&D from Palo Alto, California, to Boca Raton, Florida, citing the state's business climate and partnership opportunities, in a move emblematic of a wider coastal tech migration.
The iconic pottery maker reports encouraging sales growth and a renewed focus on its craft heritage, aiming to return to profitability next year after a period of job cuts and industry-wide challenges.
A sharp correction in Bitcoin prices has pushed MicroStrategy's massive holdings into significant paper losses, testing the resolve of the corporate sector's most vocal crypto advocate and raising questions about the sustainability of its accumulation strategy.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
A young Australian woman on a holiday with friends in Japan's Hakuba Valley has died following a horrific incident where her backpack became entangled in a moving ski lift chair, leaving her suspended.
Alibaba Group has announced a massive 3 billion yuan ($431 million) campaign to promote its Qwen AI app during the upcoming Lunar New Year holiday, significantly outpacing similar efforts by rivals Tencent and Baidu. The move intensifies a high-stakes battle for user adoption in China's rapidly evolving artificial intelligence sector.
While investors chase pure-play AI stocks, cybersecurity leader CrowdStrike demonstrates how leveraging AI defensively within a robust platform model can drive sustained, profitable growth amid escalating digital threats.
A surge of competitively priced Chinese electric vehicles and consumer goods is rapidly transforming Latin American markets, forcing governments from Mexico to Brazil to enact new tariffs and trade defenses to shield domestic industries from the influx.
A Nevada court has temporarily blocked the prediction market platform Polymarket, siding with state regulators who argue its event contracts constitute illegal gambling. The ruling intensifies a global regulatory crackdown that threatens the core business model of an emerging financial sector.
Shares of security products giant Allegion have gained significant momentum, delivering a 26% total return over the past year. With the stock now trading near $165, we examine whether its current valuation still offers an attractive entry point or if future growth is already priced in.
JPMorgan Chase confronts heightened regulatory and political pressure as a lawsuit from former President Donald Trump alleges biased account closures, while CEO Jamie Dimon's public spat with Coinbase underscores the intensifying battle between traditional banks and crypto platforms for customer funds.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
As a federal judge advances a lawsuit tying Bank of America to Jeffrey Epstein's sex trafficking network, the financial giant simultaneously positions itself at the forefront of stablecoin regulation discussions with Coinbase and the White House, creating a complex risk-and-opportunity landscape for investors.
Amidst shifting economic currents in Asia, a class of smaller companies—often overlooked as 'penny stocks'—is attracting attention for their distinct financial profiles and niche market positions. We analyze three such firms with market capitalizations below US$200 million.
As Chinese exports, from electric vehicles to e-commerce parcels, flood Latin American markets, governments are walking a tightrope between protecting domestic industries and satisfying consumer demand for affordable goods, all while navigating deepening economic ties with Beijing.
